Foundation Medicine
Foundation Medicine Monitoring Assays Show Promise for Guiding Lung Cancer Chemo-Immunotherapy
Premium
Investigators showed that patients who are positive for ctDNA at the time of their fourth induction treatment have poorer outcomes and could benefit from new strategies.
FDA Approves Foundation Medicine CDx for Use With Janssen Drug in Prostate Cancer Patients
The test will be used as a companion diagnostic for patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer.
The projects signal ongoing concern among health regulators about the quality and regulation of lab-developed tests used to guide cancer treatment and gauge disease risk.
Top Five Articles on 360Dx Last Week: Coverage of Cancer Tests Rescinded; FDA Clearances; and More
Last week, readers were most interested in a story about Medicare Administrative Contractor Novitas rescinding its coverage for several cancer genetic tests.
Foundation Medicine Blood Test Gets FDA Approval as CDx for Pfizer's Braftovi in Colorectal Cancer
The FDA has approved the FoundationOne Liquid CDx assay to identify patients with BRAF V600E alterations eligible for treatment with Braftovi.